Etoposide is a feasible and well-tolerated alternative for doxorubicin in standard chemotherapy protocols in patients with diffuse large B-cell lymphoma (DLBCL) who cannot be treated with anthracyclines, researchers have concluded. “For patients who are not candidates for anthracyclines, a key component in R-CHOP, R-CEOP represents a valid alternative that can be used in clinical practice ...
Etoposide is ‘valid’ alternative to doxorubicin in DLBCL patients with cardiac problems
By Dave Levitan
15 Mar 2021